FDA Embraces Controversy Among Reasons To Convene Advisory Committees
This article was originally published in The Tan Sheet
Executive Summary
Applications for Rx-to-OTC switches will continue to be reviewed in advisory committee meetings because they often meet FDA's reasons to seek an advisory panel's recommendation under a proposed guidance
You may also be interested in...
Advisory Committee Vacancies Remain High As FDA Revs Up Search
With its recent hiring push drawing attention, FDA is quietly undertaking another recruitment effort - filling advisory committee roster vacancies
FDA Aims To Boost Transparency Through Earlier Release Of Panel Materials
FDA will post advisory committee briefing materials on its Web site at least two business days in advance of meetings, doubling the current lead time in an effort to enhance transparency, according to a Feb. 28 draft guidance
Advisory Panel Conflict Waivers To Stay; FDA Will Provide Clarity On Process
FDA's plan for improving its advisory committee member selection process focuses on increasing the transparency and consistency of the existing process rather than an overhaul of its practices